{
    "SPADE_UN_11345": {
        "Clinical Information": [
            {
                "Medical use": "Rosacea, Acne vulgaris (II), Genital warts (II)",
                "Company": "Maruho Co., Ltd(developing), Cutanea Life Sciences, Inc.(developing), Mallinckrodt, Micrologix Biotech(Vancouver, BC, Canada)",
                "Stage of Development": "Phase III(catheter-related infections,Failure), Phase III(rosacea, completed), Phase II(atopic dermatitis (AD), usual type vulval intraepithelial neoplasia (uVIN), external genital warts, and acne vulgaris, completed), Phase III(facial seborrheic dermatitis, recruiting)",
                "Comments": "MX-594AN significantly reduced acne lesions compared with vehicle controls in a phase IIb trial in 2003 and was licensed to Cutanea Life Sciences in late 2005.",
                "Clinical Trials": [
                    "NCT00231153",
                    "NCT00608959",
                    "NCT01784133",
                    "NCT02576847",
                    "NCT03091426"
                ]
            }
        ],
        "Patent Information": [
            {
                "Patent No": "US 2005/0049182 A1",
                "Patent Link": "http://www.lens.org/lens/patent/US_2005_0049182_A1",
                "Patent Type": "Patent Application",
                "Publication Date": "2005-3-3",
                "Family Info": "CA2456477A1,DE60239707D1,EP1469876A2,EP1469876B1,US6835536,US8138144,US20030171281,US20120202735,WO2003015809A2,WO2003015809A3,WO2003015809A",
                "Patent Title": "Antimicrobial cationic peptides and formulations thereof.",
                "Abstract": "Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device."
            },
            {
                "Patent No": "US 6835536 B2",
                "Patent Link": "http://www.lens.org/lens/patent/US_6835536_B2",
                "Patent Type": "Granted Patent",
                "Publication Date": "2004-12-28",
                "Family Info": "US4510132,US6503881,US6538106,EP590070,WO9112815,WO0000214,WO0071175",
                "Patent Title": "Antimicrobial Cationic Peptides And Formulations Thereof",
                "Abstract": "Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device."
            },
            {
                "Patent No": "US 8927487 B2",
                "Patent Link": "http://www.lens.org/lens/patent/US_8927487_B2",
                "Patent Type": "Granted Patent",
                "Publication Date": "2015-1-6",
                "Family Info": "US20130296227A1,US13421018,US10865687,US10225087,US60314232,US8466102,EP0930065,WO03015809",
                "Patent Title": "Antimicrobial cationic peptides and formulations thereof",
                "Abstract": "Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganismcaused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device."
            }
        ],
        "Sequence Information": {
            "SPADE ID": "SPADE_UN_11345",
            "Peptide Name": "Omiganan (MBI-226/MX-226/CLS001)",
            "Sequence": "ILRWPWWPWRRK",
            "Source": "Omiganan (MBI-226), an analogue of indolicidin, has been proven to be capable of significantly reducing catheter colonization and microbiologically confirmed tunnel infections during catheterization",
            "Target Organism": "[Ref.19524411]Omiganan was most active against staphylococci, with MICs of 2–4, 2–8, 4 and 4 μg/mL against MSSA, MRSA, MSSE and MRSE strains, respectively. The peptide was also inhibitory against other organisms, with MICs of 8–16 μg/mL against E. coli, E. faecalis and E. faecium (including VSE and VRE strains), 128 μg/mL against E. cloacae and S. marcescens and 64 μg/mL against C. albicans.",
            "Reference": [
                "Antimicrobial and antifungal activities of a novel cationic antimicrobial peptide, omiganan, in experimental skin colonisation models.(PMID:19524411)",
                "New therapies for atopic dermatitis: Additional treatment classes.(PMID:29248520)",
                "Designing antimicrobial peptides: form follows function.(PMID:22173434)",
                "Cationic antimicrobial peptides in clinical development, with special focus on thanatin and heliomicin.(PMID:21964560)"
            ],
            "Biological Activity": [
                "Antibacterial"
            ],
            "Frequent Amino Acids": "WRP",
            "Absent Amino Acids": "ACDEFGHMNOQSTUVY",
            "Basic Residues": 4,
            "Acidic Residues": 0,
            "Hydrophobic Residues": 8,
            "Polar Residues": 4,
            "Positive Residues": 4,
            "Negative Residues": 0,
            "Mass": 1780.13,
            "PI": 12.0,
            "Net Charge": 4,
            "Hydrophobicity": -1.32,
            "Similar Sequences": [
                {
                    "SPADE_ID": "SPADE_UN_00377",
                    "Similarity": 1.0,
                    "Sequence": "ILRWPWWPWRRKM"
                },
                {
                    "SPADE_ID": "SPADE_UN_01067",
                    "Similarity": 1.0,
                    "Sequence": "ILRWPWWPWRRKIMILKKAGS"
                },
                {
                    "SPADE_ID": "SPADE_UN_01068",
                    "Similarity": 1.0,
                    "Sequence": "ILRWPWWPWRRKMILKKAGS"
                }
            ]
        }
    }
}